Factor VIII deficiency+1
RecruitingA study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B
A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B
- Disease:Factor VIII deficiencyFactor IX deficiency
- Substances:Fidanacogene ElaparvovecGiroctocogene Fitelparvovec
France- Participants:18–64 years
- Substances:Fidanacogene Elaparvovec
- Sponsor:Pfizer Inc.



